Literature DB >> 6401833

Cephalosporin antibiotics.

R L Thompson, A J Wright.   

Abstract

Cephalosporin antibiotics are bactericidal against most gram-positive cocci and gram-negative bacilli of clinical importance. They are relatively nontoxic but like the penicillins may cause hypersensitivity reactions. Agents with clinically advantageous pharmacokinetics include cefazolin, moxalactam, and cefadroxil. First-generation cephalosporins are indicated for surgical prophylaxis and for treatment of most staphylococcal and streptococcal infections in patients who are allergic to penicillins. Activity against gram-negative bacilli increases from first- to third-generation drugs, but sensitive isolates should be treated with first-generation agents to prevent resistance to newer cephalosporins and to minimize the expense for the patient. Treatment of Bacteroides fragilis and Pseudomonas aeruginosa infections is not entirely satisfactory with currently available agents. No cephalosporin is active against the enterococci, and superinfection with these organisms has occurred during treatment with moxalactam. Some experimental cephalosporins have improved activity against P. aeruginosa and gram-negative bacilli that are resistant to multiple drugs. A few of these agents have a very long half-life. It is likely that cephalosporin antibiotics will continue to proliferate.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401833

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

Review 1.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

2.  Toxic and adverse reactions encountered with new beta-lactam antibiotics.

Authors:  M F Parry
Journal:  Bull N Y Acad Med       Date:  1984-05

3.  Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits.

Authors:  R L Baker; R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

Review 4.  Antibacterial therapy in patients with malignancies.

Authors:  K H Mayer; S M Opal
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Influence of the developmental state of valvular lesions on the antimicrobial activity of cefotaxime in experimental enterococcal infections.

Authors:  P M Sullam; T A Drake; M G Täuber; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  Comparison of moxalactam and cefazolin as prophylactic antibiotics during cesarean section.

Authors:  W Rayburn; M Varner; R Galask; C R Petzold; E Piehl
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

Review 7.  Current guidelines on the use of antibacterial drugs in patients with malignancies.

Authors:  K H Mayer; O H DeTorres
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.